Prescient Therapeutics Ltd Sustainability Reports

Prescient Therapeutics Limited is a clinical-stage oncology company that develops targeted therapies and personalized medicine approaches to treat various forms of cancer. Its pipeline includes novel compounds and cell therapy platforms such as OmniCAR, PTX-100, and PTX-200.

Sector: Manufacturing

Country: Australia

Exchange: Australian Securities Exchange

LEI: 529900U1VPNYOW01NM37

FIGI: BBG001S9SH09

5 reports from 2018 to 2025

• Prescient Therapeutics Ltd 2025 Corporate Governance Statement
• Prescient Therapeutics Ltd 2025 Appendix 4E Preliminary Final Report
• Prescient Therapeutics Ltd 2024 Annual Report
• Prescient Therapeutics Ltd 2020 Annual Report
• Prescient Therapeutics Ltd 2018 Annual Report